PreviousNextExpandCollapseSearch

Web Page-TreatmentAgent

Treatment Phase Disease Study No. Summary Status Total
Hide details for 1-methyl-D-tryptophan (indoximod)1-methyl-D-tryptophan (indoximod)
  1
Hide details for Phase IIPhase II
  1
  Breast  2014-0444   A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination with a Taxane Chemotherapy in Metastatic Breast Cancer  Open  
Hide details for 111In-ibritumomab tiuxetan111In-ibritumomab tiuxetan
  2
Hide details for Phase IIPhase II
  2
  Leukemia  2011-0393   Dose-Intense Yttrium-90 Ibritumumab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies  Open  
  Lymphoma  2011-0393   Dose-Intense Yttrium-90 Ibritumumab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies  Open  
Hide details for 177Lu-DOTA0-Tyr3-Octreotate177Lu-DOTA0-Tyr3-Octreotate
  1
Hide details for Phase IIIPhase III
  1
  Gastrointestinal  2013-0016   A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III study Comparing Treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients with Inoperable, Progressive, Somatostatin Receptor Positive, Midgut Carcinoid Tumours (AAA-III-01).  Open  
Hide details for 18F-PEG6-IPQA18F-PEG6-IPQA
  1
Hide details for Phase IPhase I
  1
  Lung  2009-0832   A phase I study of 18F-PEG6-IPQA as a PET Imaging Agent for Active/Mutant EGFR Expression in Tumors  Open  
Hide details for 2-Chlorodeoxyadenosine2-Chlorodeoxyadenosine
  1
Hide details for Phase IIPhase II
  1
  Leukemia  2004-0223   PHASE II STUDY OF 2-CHLORODEOXYADENOSINE (2CDA) FOLLOWED BY RITUXIMAB IN HAIRY CELL LEUKEMIA  Open  
Hide details for 5-Azacytidine5-Azacytidine
  6
Hide details for Phase IPhase I
  1
  Leukemia  2011-0188   Phase I/II Study of Cytarabine or 5-Azacitidine Combined With Tosedostat to Evaluate the Safety and Tolerability in Older Patients with Acute Myeloid Leukemia (AML) or High Risk MDS  Open  
Hide details for Phase I/Phase IIPhase I/Phase II
  2
  Leukemia  2013-0706   A Phase I/II Study of Weekly Schedule Of Brentuximab Vedotin Alone and In Combination With 5-Azacytidine In CD30-Positive Relapsed/Refractory Acute Myeloid Leukemia  Open  
  Leukemia  2012-1047   Phase I/II Study of the Combination of Quizartinib (AC220) with 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)  Open  
Hide details for Phase IIPhase II
  3
  Leukemia  2014-0862   An Open-label Phase II Study of Lirilumab (BMS-986015) in Combination with 5-azacytidine (vidaza) for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia  Open  
  Leukemia  2014-0861   An Open-label Phase II Study of Nivolumab (BMS-936558) in Combination with 5-azacytidine (Vidaza) for the Treatment of Patients with Refractory/ Relapsed Acute Myeloid Leukemia  Open  
  Leukemia  2014-0076   Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients with Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome with FLT3-ITD Mutation  Open  
Hide details for 5-Fluorouracil5-Fluorouracil
  3
Hide details for Phase I/Phase IIPhase I/Phase II
  1
  Esophagus  2009-0847   Phase I/II Study of Evaluating the Safety and Efficacy of Using a Simultaneous Integrated Boost for Dose Escalation in Patients with Esophageal Cancer  Open  
Show details for Phase IIPhase II
  1
PreviousNextExpandCollapseSearch